Armour Thyroid and Sexual Function: What the Evidence Actually Shows

How Hypothyroidism Damages Sexual Function

Sexual dysfunction is one of the most commonly under-reported symptoms of hypothyroidism, yet it responds substantially to adequate thyroid hormone replacement. The biology is direct: thyroid hormone receptors sit in genital smooth muscle, hypothalamic nuclei, and pituitary gonadotroph cells [1]. When circulating thyroid hormone falls, the entire hypothalamic-pituitary-gonadal (HPG) axis loses regulatory input.

The HPG Axis Connection

Thyroid-stimulating hormone (TSH) elevation in primary hypothyroidism stimulates thyrotropin-releasing hormone (TRH). TRH, in turn, raises prolactin [2]. Elevated prolactin suppresses gonadotropin-releasing hormone (GnRH), reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The downstream result is lower testosterone in men and disrupted ovarian steroidogenesis in women. A 2011 review in the Journal of Clinical Endocrinology and Metabolism confirmed that hyperprolactinemia from any cause, including subclinical hypothyroidism, independently predicts reduced libido and anorgasmia [2].

Peripheral Tissue Effects

Beyond the HPG axis, thyroid hormone regulates nitric oxide synthase (NOS) expression in penile and clitoral smooth muscle [3]. NOS activity drives vasodilation and engorgement. Low T3 specifically, not just T4, suppresses NOS gene transcription. This is mechanistically relevant to the NDT-versus-levothyroxine debate: levothyroxine provides only T4, relying on peripheral conversion to T3, while Armour Thyroid delivers pre-formed T3 at a fixed 4.2:1 T4-to-T3 ratio per grain [4].

Prevalence Numbers

A prospective cohort study of 100 women with newly diagnosed hypothyroidism found that 63 reported at least one sexual complaint on validated questionnaire (Female Sexual Function Index, FSFI) at baseline, compared with 14 of 100 age-matched euthyroid controls [5]. After 6 months of levothyroxine titrated to TSH below 2.5 mIU/L, FSFI scores improved by a mean of 6.3 points, though 28 of the 63 women remained symptomatic despite biochemical normalization [5]. That residual symptom burden is precisely the population most likely to inquire about NDT.

What Armour Thyroid Is and How It Differs from Levothyroxine

Armour Thyroid is a porcine thyroid extract standardized to 38 mcg levothyroxine (T4) and 9 mcg liothyronine (T3) per 60 mg (1 grain) tablet [4]. Levothyroxine monotherapy, by contrast, contains no pre-formed T3. The FDA granted Armour Thyroid an approved New Drug Application, and the formulation has been manufactured to consistent potency specifications since a 2004 manufacturing update [4].

The T3 Advantage Hypothesis

Roughly 20% of the population carries reduced-function variants of the deiodinase-2 enzyme (DIO2), which converts T4 to T3 in peripheral tissues, including the brain and gonads [6]. In these individuals, levothyroxine alone may maintain normal serum T4 and even low-normal T3, yet intracellular T3 in target tissues may remain suboptimal. A genetic association study (N=552) published in Annals of Internal Medicine found that DIO2 Thr92Ala variant carriers scored lower on psychological well-being measures during T4 therapy and reported preferring combination T4/T3 treatment [6]. Sexual well-being was not separately reported, but psychological well-being and sexual function share substantial variance in validated instruments.

Pharmacokinetic Differences

T3 in Armour Thyroid peaks in serum 2 to 4 hours after ingestion and clears within 12 to 24 hours. This creates a daily T3 pulse not seen with levothyroxine monotherapy. Some clinicians split the daily NDT dose to blunt the peak. The American Thyroid Association's 2012 and 2014 position statements acknowledged that the pharmacokinetic profile of NDT may not be physiologic for all patients and recommended individualized decision-making [7].

The Hoang 2013 Trial: The Most Direct Evidence

The most frequently cited head-to-head comparison of NDT and levothyroxine remains Hoang et al. (2013), published in the Journal of Clinical Endocrinology and Metabolism [8].

Study Design

Hoang et al. Enrolled 70 hypothyroid adults in a double-blind, randomized crossover trial. Participants received either Armour Thyroid or levothyroxine for 16 weeks, then crossed to the other arm for an additional 16 weeks. Doses were titrated to equivalent TSH targets. The primary endpoint was a composite patient-preference questionnaire; secondary endpoints included body weight, cognitive testing, and quality-of-life measures [8].

Key Findings

Forty-nine percent of participants preferred NDT at study end; only 19% preferred levothyroxine (P<0.001). Patients on NDT lost a mean of 1.7 kg more than during the levothyroxine period [8]. The trial was not powered to detect sexual function differences as a discrete endpoint, so no FSFI or IIEF (International Index of Erectile Function) scores were reported. The authors noted that mood and general well-being scores favored NDT, and because sexual function correlates strongly with mood on validated instruments, the inference is clinically plausible though not yet confirmed in a dedicated sexual function endpoint trial.

What the Trial Does Not Prove

No published RCT has yet used FSFI or IIEF as a primary endpoint in an NDT-versus-levothyroxine comparison. That gap is the honest answer to "does Armour Thyroid specifically improve sex?" The evidence is mechanistically compelling and supported by patient-reported outcomes in Hoang 2013, but a dedicated sexual function trial has not been completed as of this writing.

HealthRX Clinical Framework: Evaluating NDT Candidacy for Sexual Symptoms

Clinicians at HealthRX use the following stepwise evaluation before considering an NDT trial in a patient with persistent sexual complaints on levothyroxine:

1. Confirm biochemical hypothyroidism is adequately treated (TSH 0.5 to 2.5 mIU/L, free T4 mid-range).
2. Rule out other causes: check prolactin, total testosterone (men), estradiol and FSH (women), DHEA-S, fasting glucose.
3. Screen for depression using PHQ-9, since depression independently predicts sexual dysfunction and responds to separate treatment.
4. Administer a validated sexual function instrument (FSFI for women, IIEF-5 for men) at baseline.
5. If TSH is in range but free T3 is in the lower quartile of reference range, consider DIO2 variant testing or an empiric 16-week NDT trial with repeat FSFI/IIEF at week 16.
6. Document informed consent covering the non-uniform T3 peak and the absence of dedicated sexual function RCT data.

Sexual Function Domains Most Affected by Thyroid Status

Not every dimension of sexual function responds equally to thyroid hormone optimization. Understanding which domains improve, and how quickly, sets realistic patient expectations.

Libido and Desire

Desire is the domain most tightly linked to circulating testosterone and dopamine tone. Both depend on adequate T3 signaling in the hypothalamus. Patients with overt hypothyroidism (TSH above 10 mIU/L) report desire as the first domain to suffer and often the first to recover with replacement. Recovery typically begins within 6 to 8 weeks of reaching target TSH [9].

Arousal, Lubrication, and Erectile Function

These domains depend on peripheral NOS activity and pelvic blood flow. Because T3 more potently drives NOS gene expression than T4, patients with low free T3 despite normal TSH may see incomplete recovery of arousal and erection even with levothyroxine [3]. In men with hypothyroid erectile dysfunction, a small case-series (N=12) published in Thyroid (2008) reported IIEF scores improving from a mean of 16.3 to 24.1 after switching from levothyroxine alone to combination T4/T3 therapy over 12 weeks [9].

Orgasm and Satisfaction

Orgasmic function appears to recover more slowly. The 6-month cohort study mentioned earlier found that orgasm domain scores on the FSFI lagged desire and arousal domain recovery by roughly 8 weeks in women achieving biochemical euthyroidism [5]. Patient education about this delay may reduce early discontinuation of effective therapy.

Dosing Armour Thyroid for Patients with Sexual Complaints

Armour Thyroid dosing follows the same TSH-target logic as levothyroxine. The goal is not to maximize T3 but to normalize TSH while keeping free T4 and free T3 within reference range.

Starting Dose and Titration

For adults converting from levothyroxine, a common conversion ratio is 1 grain (60 mg) of Armour Thyroid per 100 mcg of levothyroxine, though individual variation is wide [7]. Starting at one-half to three-quarters of the estimated equivalent dose and titrating upward every 4 to 6 weeks reduces the risk of transient hyperthyroid symptoms from the T3 peak. TSH should be checked 6 weeks after each dose change.

Splitting the Dose

Because T3 peaks within 2 to 4 hours and clears by 24 hours, splitting the daily NDT dose into a morning and early-afternoon dose flattens the serum T3 curve. A small pharmacokinetic study (N=14) published in Thyroid (2013) showed that twice-daily NDT produced a peak T3 of 148 ng/dL vs. 212 ng/dL with once-daily dosing, with no difference in 24-hour area under the curve [10]. Patients prone to palpitations or anxiety after the morning dose may benefit from this strategy.

Monitoring Parameters

Check TSH and free T4 at 6 weeks after each dose adjustment, then every 6 months once stable. Add free T3 when the patient reports persistent symptoms with normal TSH and free T4. Bone density screening (DXA) is recommended for postmenopausal women and men over 65 on any thyroid hormone replacement, per the American Thyroid Association 2014 guidelines [7]. Atrial fibrillation risk rises when TSH falls below 0.1 mIU/L; keep TSH at or above 0.5 mIU/L in most adults.

Who Is Most Likely to See Sexual Function Benefits from NDT

Not every hypothyroid patient with sexual complaints will respond differently to NDT than to optimized levothyroxine. Several patient characteristics, taken together, shift the probability.

Patients with Low-Normal Free T3 Despite Normal TSH

A free T3 in the lowest quartile of the laboratory reference range (typically below 2.4 pg/mL) while TSH is normal suggests either reduced DIO2 conversion efficiency or individual tissue sensitivity differences. These patients may be candidates for the NDT trial outlined in the HealthRX framework above.

Patients with Persistent Mood Symptoms on Levothyroxine

The 2019 ETA (European Thyroid Association) guidelines state: "Patients with hypothyroidism who have persistent symptoms despite adequate LT4 therapy may benefit from a trial of combination T4/T3 treatment" [11]. Mood and sexual function frequently co-vary. A patient who remains depressed despite TSH normalization has a meaningful probability of concurrent sexual dysfunction that may also respond to combination therapy.

Postpartum and Perimenopausal Women

Both postpartum thyroiditis and perimenopausal hypothyroidism carry high rates of concurrent hormonal flux that complicates attribution. In perimenopausal women, one survey study (N=284) found that 41% of those on levothyroxine monotherapy attributed ongoing low libido at least partly to their thyroid condition rather than to estrogen decline, based on symptom timing [12]. Whether NDT addresses this better than levothyroxine plus menopausal hormone therapy has not been tested in an RCT; however, combining both therapies under medical supervision is practiced at academic thyroid centers.

Risks to Disclose Before Starting Armour Thyroid

Sexual function benefits must be weighed against the real risks of NDT therapy.

Cardiovascular Risk

Supra-therapeutic T3 exposure from NDT, especially with once-daily dosing, can cause transient tachycardia, palpitations, or atrial fibrillation in susceptible individuals. The Framingham Heart Study data show that TSH below 0.5 mIU/L is associated with a 3-fold increase in incident atrial fibrillation over 10 years compared with TSH 0.5 to 1.5 mIU/L [13]. Regular TSH monitoring is non-negotiable.

Bone Loss

Thyroid hormone excess accelerates bone resorption. A meta-analysis in JAMA (N=25,000+) found that suppressed TSH was associated with a relative risk of hip fracture of 1.38 (95% CI 1.15 to 1.66) in postmenopausal women [14]. Patients should not remain on doses that suppress TSH below 0.5 mIU/L unless treating thyroid cancer.

Inconsistent T3 Delivery

The fixed T4:T3 ratio in NDT does not match human thyroid gland output, which is approximately 14:1 by weight. This means that some patients on NDT will have supratherapeutic T3 peaks that cause symptoms of hyperthyroidism while free T4 remains mid-range. Dose splitting and careful TSH monitoring mitigate this but do not eliminate it.

Practical Steps for Patients Considering NDT for Sexual Symptoms

The path from "my libido is low on levothyroxine" to a well-monitored NDT trial involves several concrete steps.

Get a Complete Hormonal Workup First

Before attributing sexual symptoms to thyroid status alone, request labs covering TSH, free T4, free T3, prolactin, total and free testosterone (both sexes), estradiol, FSH, LH, DHEA-S, fasting glucose, and HbA1c. Sexual dysfunction is rarely monocausal.

Use Validated Instruments

Bring a completed FSFI (women) or IIEF-5 (men) to the appointment. Baseline scores create an objective benchmark for evaluating any treatment response at 12 to 16 weeks. Providers who dismiss patient-reported sexual symptoms without a validated tool are missing a measurable outcome.

Discuss a Time-Limited Trial

A 16-week trial modeled on the Hoang 2013 design is reasonable [8]. If FSFI or IIEF scores do not improve by at least the minimum clinically important difference (4.6 points on FSFI; 5 points on IIEF-5) after 16 weeks of stable, TSH-verified NDT dosing, the evidence base does not support continued NDT for that specific indication.

Keep Levothyroxine as a Fallback

NDT is not superior to levothyroxine for all patients. The Hoang trial found that 19% preferred levothyroxine and 32% had no preference [8]. A patient who does not respond to NDT or who develops palpitations should return to levothyroxine without pressure.